COST EFFECTIVENESS OF BORTEZOMIB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR THE FIRST-LINE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
EHA Library, Marjolijn van Keep,
100656
IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
EHA Library, Paula Cramer,
101332
PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF(POST-ET MF)
EHA Library, Tomonori Uno,
101341
Eloquent-2: A phase 3, randomized, open-label study of lenalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma
EHA Library, Meletios Dimopoulos,
103089
UPDATED OVERALL SURVIVAL ANALYSIS OF THE FIRST STUDY: CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS MELPHALAN, PREDNISONE, AND THALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Library, Thierry Facon,
103068
PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF AG-348, A FIRST-IN-CLASS ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R, IN HEALTHY SUBJECTS
EHA Library, Hua Yang,
103061